Ardelyx

About Ardelyx

Ardelyx Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative medicines for patients with unmet medical needs related to gastrointestinal and cardiorenal diseases. Its products include IBSRELA, a minimally absorbed small molecule therapy for irritable bowel syndrome with constipation, and XPHOZAH, a phosphate absorption inhibitor for reducing serum phosphorus in adults with chronic kidney disease on dialysis. Ardelyx develops pharmaceuticals that target specific transporters, channels, and receptors in the gastrointestinal tract to address mineral metabolism imbalances and metabolic disorders.